Novel coronavirus pneumonia has been approved by American Pharmaceutical Company Pfizer and BioNTech, a two person familiar with the matter, and has been granted a new crown vaccine to WHO led COVAX.
The size of the deal or the unit price of the vaccine between Pfizer and biontech and covax is unclear, Reuters reported Tuesday. But the source said the size of the vaccine available may be relatively small. Another source said that these limited vaccines are mainly supplied to medical staff in covax countries. The official news is expected to be released on the 23rd. Previously, who announced on December 31 last year that it would issue its first new crown vaccine emergency use certification to the vaccine jointly developed by Pfizer and biontech.
The World Health Organization announced on the 8th that covax has implemented a contract for 2 billion doses of vaccine, which will be distributed to participating economies immediately after the delivery of the vaccine. So far, covax has reached future vaccine supply cooperation with AstraZeneca, Oxford University, Serum Institute of India, Sanofi and its partner GlaxoSmithKline.
The novel coronavirus pneumonia vaccine implementation plan novel coronavirus pneumonia was launched by the WHO and the global alliance for vaccines and immunization and the innovation alliance of epidemiology prevention. It is expected to provide 2 billion new doses of pneumonia vaccine to the world by the end of 2021.